老年乳腺癌患者乳房切除联合即刻重建:全国癌症数据库研究
基于美国国家癌症数据库2004至2012年364,767例乳腺癌乳房切除患者,35.0%接受即刻乳房重建(IBR)。IBR患者中10.3%年龄≥65岁,≥65岁女性M+IBR从6.7%增至18.1%(p<0.001),与<65岁女性平行上升。老年M+IBR患者30天非计划再入院率较高(3.7% vs 2.9%,p<0.001),提示需建立安全筛选标准。
要点
- 老年(≥65岁)乳腺癌患者M+IBR使用率从2004年6.7%升至2012年18.1%。
- 老年M+IBR患者对侧预防性乳房切除率低于年轻患者(27.4% vs 45.9%)。
- 老年M+IBR患者30天非计划再入院率较高(3.7% vs 2.9%)。
核心结论
- M+IBR在老年乳腺癌患者中应用增加,但老年患者30天非计划再入院率较高,需建立安全筛选标准。
研究设计与样本
- 回顾性队列研究,数据来自美国国家癌症数据库2004至2012年,共纳入364,767例因乳腺癌行乳房切除术的患者。
主要发现
- 全部乳房切除患者中127,501例(35.0%)接受IBR;M+IBR患者中10.3%年龄≥65岁,1.5%年龄≥75岁。
- ≥65岁女性M+IBR比例从2004年6.7%升至2012年18.1%(p<0.001),<65岁女性从32.9%升至57.3%(p<0.001)。
- M+IBR患者中对侧预防性乳房切除率≥65岁为27.4%,<65岁为45.9%(p<0.001)。
- M+IBR患者中Charlson-Deyo评分>0的比例≥65岁为18.4%,<65岁为9.8%(p<0.001);单纯乳房切除的≥65岁患者中该比例为27.0%。
- M+IBR患者30天非计划再入院率≥65岁为3.7%,<65岁为2.9%;Charlson-Deyo评分=0者分别为3.5%和2.8%(均p<0.001)。
临床怎么用
- 对≥65岁乳腺癌患者考虑M+IBR时,应评估年龄和合并症对30天非计划再入院风险的影响。
- 老年M+IBR患者对侧预防性乳房切除率较低,决策时需结合个体情况。
局限性
- 原文未报告具体局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mastectomy with immediate breast reconstruction (M+IBR) is performed increasingly for breast cancer treatment, but whether this trend extends to the growing number of women diagnosed at age 65 or older is unknown. We studied the effects of age and comorbidities on the use and outcomes of M+IBR. STUDY DESIGN: Patients undergoing mastectomy for breast cancer were ascertained from the National Cancer Data Base 2004 to 2012. Performance of M+IBR and outcomes were compared by age group (<65 years vs ≥65 years) and other patient and tumor factors. RESULTS: There were 364,767 patients who underwent mastectomy, of whom 127,501 (35.0%) had IBR. Among M+IBR patients, 10.3% were age 65 or older, including 1.5% who were 75 or older. From 2004 to 2012, M+IBR increased from 6.7% to 18.1% in women 65 or older (p < 0.001), paralleling the increase in women less than 65 years (32.9% to 57.3%; p < 0.001). Contralateral prophylactic mastectomy rates in M+IBR patients were lower in patients 65 or older (27.4%) than in those less than 65 (45.9%), p < 0.001. A Charlson-Deyo score > 0 (any comorbidity) was more frequent in patients 65 or older having mastectomy alone (27.0%) vs M+IBR (18.4 %) (p < 0.001). Among M+IBR patients, the Charlson-Deyo score was >0 in 18.4% of patients 65 or older vs 9.8% among patients less than 65 (p < 0.001). Thirty-day unplanned readmission rates were higher for older patients: 3.7% vs 2.9% for M+IBR patients 65 or older vs less than 65, respectively, even those with a Charlson-Deyo score = 0, 3.5% vs 2.8% (both p < 0.001). CONCLUSIONS: Rates of M+IBR rates are increasing, with 10% of M+IBR patients now age 65 or older. Higher 30-day unplanned readmission rates in elderly M+IBR patients with or without comorbidities suggest the need to establish criteria for safe M+IBR in these patients.
引用
- Gibreel WO, Day CN, Hoskin TL, et al. Mastectomy and Immediate Breast Reconstruction for Cancer in the Elderly: A National Cancer Data Base Study. J Am Coll Surg. 2017. PMID: 28238934. doi:10.1016/j.jamcollsurg.2016.12.051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。